300 Shire Way
Lexington, MA 02421
United States
www.shire.com

Statement for MPS Societies
December 17, 2013

We appreciate the distress and the challenge caused by rare diseases, and Hunter syndrome in particular, and we are dedicated to finding new ways to treat conditions with high unmet medical need. We also know that for many families, not having access to any experimental therapy is heartbreaking.

While some safety data is available for our intrathecal program SHP-609, more is required, and very importantly, no clinical trial has yet been conducted which has been primarily designed to study efficacy. As a result, we cannot provide access to any patient at this stage outside the clinical trial setting. We are focused on the next phase of clinical development for SHP-609 in the hope that it will lead to a safe, effective, and approved treatment for patients around the world suffering the CNS aspects of Hunter syndrome.